Randomized trial · people

Tesamorelin: 10.9% less visceral fat at 6 months in HIV patients

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with HIV and excess belly fat, tesamorelin reduced deep belly fat while it was taken, and the effect faded quickly after it was stopped.

Kind
Randomized trial
Studied in
People
Number studied
404
Published
2010
Journal
J Acquir Immune Defic Syndr

What they tested

The team tested whether daily tesamorelin reduces deep belly fat in people with HIV on antiretroviral therapy who carry excess abdominal fat.

How the study was done

A double-blind, randomized, placebo-controlled trial in 404 people with HIV and excess abdominal fat. For the first 6 months they got 2 mg tesamorelin under the skin daily or placebo (a dummy shot) in a 2:1 ratio; then, for months 6 to 12, the tesamorelin group was randomized again to keep taking it or switch to placebo, and the placebo group switched to tesamorelin.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 6 months, visceral fat (the deep fat around the organs) fell by 10.9% (21 cm2) on tesamorelin vs 0.6% (1 cm2) on placebo. Trunk fat, waist size and waist-hip ratio also improved, while fat under the skin of the belly and limbs did not change. IGF-1, a growth-related hormone, went up with no change in blood sugar measures, and both patients' distress about belly appearance and doctors' ratings of belly profile improved. Those who stayed on tesamorelin for 12 months had about 18% less visceral fat, but people who switched to placebo after 6 months quickly lost their early gains.

What it doesn’t show

The trial only included people with HIV on antiretroviral therapy who had excess belly fat, so it does not show effects in other groups. It ran 12 months, and the benefit faded fast after stopping, so it does not show lasting effects off the drug.

The paper

Falutz et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010.

The compound

More studies on Tesamorelin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tesamorelin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo